News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Mark Wildgust: Outstanding Results from the FLAIR Study Presented at EHA25
Mark Wildgust/X
Jun 17, 2025, 09:59

Mark Wildgust: Outstanding Results from the FLAIR Study Presented at EHA25

Mark Wildgust, Vice President, Global Medical Affairs, Oncology at The Janssen Pharmaceutical Companies of Johnson and Johnson, shared a post on X:

“Outstanding results from the FLAIR study presented at EHA25 today and published in the ⁦NEJM.”

Title: Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia

Journal: NEJM

Authors: Talha Munir, Sean Girvan, David A. Cairns, Adrian Bloor, David Allsup, Abraham M. Varghese, Satyen Gohil, Shankara Paneesha, Andrew Pettitt, Toby Eyre, Christopher P. Fox, Francesco Forconi, Constantine Balotis, Nicholas Pemberton, Oonagh Sheehy, John Gribben, Nagah Elmusharaf, Simona Gatto, Gavin Preston, Anna Schuh, Renata Walewska, Lelia Duley, Nichola Webster, Surita Dalal, Andrew Rawstron, Dena Howard, Anna Hockaday, Sharon Jackson, Natasha Greatorex, Sue Bell, David Stones, Julia M. Brown, Piers E.M. Patten, Peter Hillmen

Read the full article.

FLAIR Study

Read “25 Posts Not to Miss from EHA 2025“.

FLAIR Study

Abraham M. Varghese Adrian Bloor Andrew Pettitt Andrew Rawstron Anna Hockaday Anna Schuh cancer Christopher P. Fox Constantine Balotis David A. Cairns David Allsup David Stones Dena Howard EHA EHA 2025 EHA25 FLAIR FLAIR study Francesco Forconi Gavin Preston Janssen Pharmaceutical Companies of Johnson and Johnson John Gribben Julia M. Brown Lelia Duley Mark Wildgust Nagah Elmusharaf Natasha Greatorex NEJM Nichola Webster Nicholas Pemberton OncoDaily Oncology Oonagh Sheehy Peter Hillmen Piers E.M. Patten Renata Walewska Satyen Gohil Sean Girvan Shankara Paneesha Sharon Jackson Simona Gatto Sue Bell Surita Dalal Talha Munir Toby Eyre
Special Coverage
Insight
Jun 17, 2025, 09:59
Mark Wildgust: Outstanding Results from the FLAIR Study Presented at EHA25
Blog
Jun 17, 2025, 09:57
Anna Sureda: Excellent EHA-EBMT Joint Session at EHA 2025 in Milan
Blog
Jun 17, 2025, 09:56
Yan Leyfman: Great Presentation about the Promise of Armored CAR T cells without Lymphodepletion Therapy
Blog
Jun 17, 2025, 09:55
Asim Belgaumi: Working with Pakistan on the Global Platform for Access to Childhood Cancer Medicines
Insight
Jun 17, 2025, 09:52
Toby Eyre Shared NEJM Article on Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia
Blog
Jun 17, 2025, 09:45
Are We Truly Addressing the Whole Person in Cancer Care? - SPCC
Science
Jun 17, 2025, 09:33
Rasha Aboelhassan: A New Ray of Hope for Stage III NSCLC with Neoadjuvant Immunotherapy
Career
Jun 17, 2025, 09:28
David Atallah: Honored to Receive 2025 Researcher Award and Outstanding Career from Salim Daccache and Richard Maroun
Science
Jun 17, 2025, 09:11
Myeloma Paper of the Day, June 17th, suggested by Robert Orlowski
Blog
Jun 17, 2025, 09:10
Join AACR in celebrating National Cancer Survivor Month
Blog
Jun 17, 2025, 09:05
Richard Scolyer Honored with Inaugural Award at Tour de Cure Snow Ball Event
Blog
Jun 17, 2025, 08:55
The Pillar 3 of the National Cancer Control Strategy - National Cancer Institute of Kenya